NeuroSense Therapeutics Ltd. successfully conducted its Annual General Meeting of Shareholders on June 27, 2024. During the meeting, shareholders voted in favor of all proposed resolutions that were previously detailed in the company's Notice and Proxy Statement, which was furnished to the Securities and Exchange Commission on May 28, 2024. The outcomes of the meeting are now incorporated by reference into the company's existing Registration Statements on Form F-3 and Form S-8, enhancing their validity from the date of this report submission. This event is significant as it reflects shareholder approval of the company's proposed actions and strategic direction.

NeuroSense Therapeutics Ltd. successfully conducted its Annual General Meeting of Shareholders on June 27, 2024. During the meeting, shareholders voted in favor of all proposed resolutions that were previously detailed in the company's Notice and Proxy Statement, which was furnished to the Securities and Exchange Commission on May 28, 2024. The outcomes of the meeting are now incorporated by reference into the company's existing Registration Statements on Form F-3 and Form S-8, enhancing their validity from the date of this report submission. This event is significant as it reflects shareholder approval of the company's proposed actions and strategic direction.